What is high-tech medicine worth? And what’s a proper orientation mark for its price? A debate between the Brusselsbased biotech lobbyist Nathalie Moll and Dr. Carlos Correa, head of a think tank in Geneva that represents the interests of developing countries
Opinion
Expensive health?
What is high-tech medicine worth? And what’s a proper orientation mark for its price? A debate between the Brusselsbased biotech lobbyist Nathalie Moll and Dr. Carlos Correa, head of a think tank in Geneva that represents the interests of developing countries
